Additionally, the correlation between elevated Gli expression and poor prognosis in AML, along with the clinical approval of Glasdegib—a Hedgehog–Smoothened (SMO) inhibitor—for AML treatment [23], underscores the rationale for exploring the combined targeting of FLT3, FASN, and Gli. This evidence concerns the gene SMO and acute myeloid leukemia.